Month: April 2020

Greenway Therapeutix® is Exhibiting at the Generational Dermatology Meeting

Posted on by greenwayadmin

Greenway Therapeutix® is Exhibiting at the Generational Dermatology Meeting

Palm Springs, CA, February 14, 2020 – Greenway Therapeutix®, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was exhibiting at Generational Dermatology meeting this year in Palm Springs.

Founder and Course Director, Dr. Wendy E. Roberts indicates that Generational Dermatology™ is a multi-decade approach to the evolving aging patient, including Medical, Surgical and Aesthetic Dermatology. This CME meeting is targeted toward the Dermatologist and other CORE specialists of beginning, mid and late career.

The company’s CEO, Dr. Michael Milane, was present for the meeting and the Greenway booth support throughout the conference to address a variety of questions from clinicians in attendance. There was a lot of interest in current clinical findings on Canno Cream™, recent case studies with safety and efficacy data and potential availability for Dermatology offices.

About Greenway Therapeutix

Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.

Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.

For more information, visit www.greenwaytherapeutix.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Greenway Therapeutix® is Exhibiting at the Prestigious Maui Derm Meeting

Posted on by greenwayadmin

Greenway Therapeutix® is Exhibiting at the Prestigious Maui Derm Meeting

Maui, HI, January 25, 2020 – Greenway Therapeutix®, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was exhibiting at the prestigious Maui Derm Conference in Wailea, Maui. 

Each year Maui Derm’s lectures, panel discussions and workshops are designed to bridge the ever-widening knowledge gap by providing an in-depth look at topics vital to the practice of dermatology. The diverse and expert faculty present in-depth, cutting edge materials covering a wide array of medical, cosmetic, coding/billing and CLIA certification topics in dermatology.

Dr. George Martin, who is the founder and Program Director of the Maui Derm conference, indicated that he is excited to have Greenway Therapeutix® participating as a first-time supporter of the meeting. He also indicated that there is a large potential for the future of CBD research, education and medical products in Dermatology.

The company’s CEO, Dr. Michael Milane, CSO, Dr. Dan Siegel and Scientific Advisory Board members, Dr. Todd Schlesinger and Dr. Neal Bhatia, were present at the meeting and the Greenway booth throughout the conference to address a high number of questions from over 500+ clinicians in attendance. There was a lot of interest in current data on Canno Cream™ and when products will become available in US offices.

About Greenway Therapeutix

Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.

Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.

For more information, visit www.greenwaytherapeutix.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Greenway Therapeutix Leadership, recently interviewed by Dermatology Times on the potential of Cannabinoids in Dermatology​

Posted on by greenwayadmin

Greenway Therapeutix Leadership, Dr. Milane and Dr. Siegel, recently interviewed by Dermatology Times on the potential of Cannabinoids in Dermatology

Los Angeles, CA, January 01, 2020 – Greenway Therapeutix’s CEO, Dr. Michael Milane and CSO, Dr. Dan Siegel, were recently interviewed by the Dermatology Times about the potential of Cannabinoid therapeutics in Dermatology for various inflammatory conditions.

With public’s continued interest in CBD products, Dr. Milane indicates that “currently, there aren’t many high-quality, high-standard CBD products on the market. For the most part, they don’t reach the standards we’re accustomed to in dermatology.” and how it’s very important for us to change that.

In a market with few high-standard CBD options, Dr. Siegel says, providers should educate themselves even if they don’t intend to recommend CBD products. “My advice to providers who strive to maintain the highest standard of ethics is to be aware there aren’t any products out there right now that really deliver the expected effect,” Dr. Siegel says.

With this, Greenway Therapeutix is fully dedicated in providing data driven, medical grade CBD products for Dermatologists and other health care professionals, where they meet high industry clinical and safety standards.

Please follow the link below for the full article published on the cover of DermatologyTimes ( Volume 41, Number 1 | January 2020 ) :

Are CBD skincare products effective – DermatologyTimes.com

About Greenway Therapeutix

Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.

Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.

For more information, visit www.greenwaytherapeutix.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Greenway Therapeutix CEO, Dr. Michael Milane presents at the 2019 Autumn Dermatology Conference

Posted on by greenwayadmin

Greenway Therapeutix CEO, Dr. Michael Milane presents at the 2019 Autumn Dermatology Conference

New York, NY, November 04, 2019 – Greenway Therapeutix, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was at the 2019 Autumn Dermatology Conference in New York.

The company’s CEO, Dr. Michael Milane, presented educational information in better understanding the human internal Endocannabinoid systems and the associated inflammatory pathways. This was further expanded to how Cannabinoids work on the skin and the specific associated inflammatory cascades of immune factors.

Unique to this presentation and as one of the first times this data has been world released, Dr. Milane presented recent human clinical data on a few clinical observational cases where Atopic Dermatitis, Periorbital Dermatitis and itch have recently been observed to have high levels of efficacy with a novel formulation of Nano CBD Cream.

 

There was one clinical observational case presented on Atypical Rosacea, where the patient had failed currently prescribed treatments and responded positively with a significant reduction of symptoms in 10 days with monotherapy treatment on Nano CBD Cream. The patient was followed for 3 months of treatment with continued clearance on this regiment. This was the first clinical data ever presented on short- and long-term safety and efficacy of treatment of Rosacea with CBD.

In addition to the scientific content, Dr. Milane covered the history of Cannabis as it has been used for medicine, expanding back to 2700 BC in China and spreading through multiple cultures, such as the Egyptians, Romans and to the Americas for multiple conditions.

The Program Director, Dr. Orit Markowitz, a Board-Certified Dermatologist from New York, indicated that there is surely a need for more education, data and larger studies on safety and efficacy of these conditions with CBD use for multiple skin conditions.

About Greenway Therapeutix

Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.

Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.

For more information, visit www.greenwaytherapeutix.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.